After July surge, FDA approvals for GI settle into summer lull: What you may have missed

Following a July boom in game-changing FDA approvals for gastroenterology, including the first blood test for colorectal cancer, the agency has succumbed to the summer lull with only three approvals for GI to close out the season.
Within the last few months, the FDA has approved several notable firsts for GI and liver disease care, including AbbVie’s Skyrizi (risankizumab) as the first IL-23 inhibitor approved for both ulcerative colitis and Crohn’s disease, and the first rapid test for hepatitis C virus intended for use in point-of-care settings.
The agency also greenlit a third

Following a July boom in game-changing FDA approvals for gastroenterology, including the first blood test for colorectal cancer, the agency has succumbed to the summer lull with only three approvals for GI to close out the season.
Within the last few months, the FDA has approved several notable firsts for GI and liver disease care, including AbbVie’s Skyrizi (risankizumab) as the first IL-23 inhibitor approved for both ulcerative colitis and Crohn’s disease, and the first rapid test for hepatitis C virus intended for use in point-of-care settings.
The agency also greenlit a third